Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group).
Yokoyama Y, Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. Yokoyama Y, et al. Among authors: ebara s. Int Urol Nephrol. 2024 Nov 8. doi: 10.1007/s11255-024-04268-2. Online ahead of print. Int Urol Nephrol. 2024. PMID: 39516348
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Powles T, et al. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282910 Clinical Trial.
Prognostic factors among patients with pathological Grade Group 5 prostate cancer based on robot-associated radical prostatectomy specimens from a large Japanese cohort (MSUG94).
Sasaki T, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kawase M, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Koga F, Urakami S, Inoue T. Sasaki T, et al. Among authors: ebara s. World J Urol. 2024 Mar 14;42(1):152. doi: 10.1007/s00345-024-04864-y. World J Urol. 2024. PMID: 38483586
Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).
Toide M, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kawase M, Sasaki T, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Inoue T, Urakami S, Koga F. Toide M, et al. Among authors: ebara s. J Robot Surg. 2024 Jan 17;18(1):38. doi: 10.1007/s11701-023-01761-1. J Robot Surg. 2024. PMID: 38231428
Prognostic Importance of Lymphovascular Invasion for Specific Subgroup of Patients with Prostate Cancer After Robot-Assisted Radical Prostatectomy (The MSUG94 Group).
Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. Kawase M, et al. Among authors: ebara s. Ann Surg Oncol. 2024 Mar;31(3):2154-2162. doi: 10.1245/s10434-023-14691-x. Epub 2024 Jan 10. Ann Surg Oncol. 2024. PMID: 38200385
The Negative Impact of Inflammation-Related Parameters in Prostate Cancer after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (the MSUG94 Group).
Murase K, Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. Murase K, et al. Among authors: ebara s. J Clin Med. 2023 Dec 17;12(24):7732. doi: 10.3390/jcm12247732. J Clin Med. 2023. PMID: 38137801 Free PMC article.
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S, Iwata T, Kawada T, Okamoto Y, Sano Y, Kawago Y, Miyake S, Moriwake T, Kuinose A, Horikawa Y, Tsuboi K, Tsuboi I, Sakaeda K, Nakatsuka H, Takamoto A, Hirata T, Shirasaki Y, Yamasaki T, Morinaka H, Nagasaki N, Hara T, Ochi A, Okumura M, Watanabe T, Sekito T, Kawano K, Horii S, Yamanoi T, Nagao K, Yoshinaga K, Maruyama Y, Tominaga Y, Sadahira T, Nishimura S, Edamura K, Kobayashi T, Kusumi N, Kurose K, Yamamoto Y, Sugimoto M, Nakada T, Sasaki K, Takenaka T, Ebara S, Miyaji Y, Wada K, Kobayashi Y, Araki M. Katayama S, et al. Among authors: ebara s. Urol Oncol. 2024 Mar;42(3):70.e11-70.e18. doi: 10.1016/j.urolonc.2023.11.009. Epub 2023 Dec 20. Urol Oncol. 2024. PMID: 38129282
236 results